Refine by
For Its Bacterial Cancer Therapy Suppliers Serving Canada
108 companies found
based inBrunnthal/Hofolding, GERMANY
WISAP employs specialized staff and manufactures all products exclusively in Germany using the highest quality materials. We as WISAP have established ourselves for more than 60 years as a medium-sized niche supplier of medical instruments and ...
based inSan Diego, CALIFORNIA (USA)
Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection, at a time when intervention can bring the greatest impact for patients. Leveraging PCR-based epigenetics, our pioneering testing approach uses ...
based inMiami, FLORIDA (USA)
Veru is a biotechnology company focused on developing novel medicines for COVID-19, additional ARDS-related diseases, and for breast and prostate cancers. Veru is a Wisconsin corporation and is the successor to The Wisconsin Pharmacal Company, Inc. ...
based inDanvers, MASSACHUSETTS (USA)
Neutron Therapeutics is a medical equipment company founded in November 2015. We are working to bring Boron Neutron Capture Therapy (BNCT) out of the realm of medical research and transform it into a widely available first-line cancer therapy. We ...
A Promising Non-Invasive Therapy for Cancer Patients; Boron Neutron Capture Therapy (BNCT) is a unique type of radiation therapy that enables targeting of cancer at the cellular level. BNCT has been used to treat cancer with a non-invasive two-step ...
based inYuseong-gu, SOUTH KOREA
WON TECH Co., Ltd. established in 1999, grows up steadily and leads a medical laser equipment & Ultrasound (HIFU) market. Particularly, WONTECH realized a limitation of domestic techniques, which depend mostly on foreign technology when its ...
based inCambridge, MASSACHUSETTS (USA)
Myeloid Therapeutics is a leader in the development of mRNA-based immunotherapies, focusing on harnessing and enhancing the natural capabilities of myeloid cells to combat cancer. The company's cutting-edge in vivo engineering platform is designed ...
Emerging from the Company’s proprietary ATAK™ CAR receptor library, Myeloid’s novel in vivo engineering platform specifically targets and activates myeloid cells to elicit broader anti-tumor adaptive immunity. Through this ...
based inLondon, UNITED KINGDOM
Vision RT provides innovative Surface Guided Radiation Therapy (SGRT) solutions for cancer treatment. Vision RT was founded in 2001 with a mission to develop pioneering technology for Surface Guided Radiation Therapy (SGRT), with the goal of ...
based inAmsterdam, NETHERLANDS
Self-screen has a long history and track record in translational HPV related science. The company was founded in 2008 to advance the implementation of scientific discoveries in the field of HPV related cancer screening into routine practice. Our ...
based inGuro-gu, SOUTH KOREA
We provide diagnostic solutions throughout the cancer treatment cycle from early cancer diagnosis to prognostic and companion diagnostics as well as postoperative monitoring. Diagnose cancer as early as possible, when the disease is easiest to ...
Chemotherapy drugs have many side effects such as reduction in white blood cells, hair loss, vomiting because they attack rapidly growing cells without separating cancer cells from normal cells. However targeted therapy drugs have less side effects ...
based inMoscow, RUSSIA
NANOLEK is a modern, fast-growing Russian biopharmaceutical company, specializing in the production of import-substituting and innovative drugs. Our high-tech full-cycle production facilities fully comply with GMP and ISO standards. Our portfolio ...
based inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
Zymeworks’ lead product candidate, zanidatamab, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric platform. Zanidatamab is currently being evaluated in global Phase 1, Phase 2 and pivotal clinical trials as ...
based inToronto, ONTARIO (CANADA)
Theralase was one of the first companies in North America to bring CLT to patients and the first company in the world to bring personalized ACT to patients individual tissue characteristics. With our multi-discipline experience in physics, ...
Theralase is laser focused on advancing the cutting-edge Anti-Cancer Therapy (“ACT”) towards commercialization, providing an alternative treatment methodology for Non-Muscle Invasive Bladder Cancer (“NMIBC”) patients ...
based inLondon, UNITED KINGDOM
Getting ahead of cancer is crucial no matter where people are in their cancer journey. From earlier cancer detection to treatment guidance and monitoring, we are helping people get the answers they need to make more informed decisions across the ...
based inDoylestown, PENNSYLVANIA (USA)
Neuropathix, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing a patented product platform of novel molecules from our proprietary socially responsible pain management therapeutics to treat patients with a ...
Neuropathix has focused its science on the research and development of a pipeline of next generation socially responsible pain management ...
based inPetah Tikva, ISRAEL
Isotopia Molecular Imaging was established in 2007 by renowned Israeli scientists and experts in the field of radio pharmaceuticals, and in collaboration with the International Metronotario investment organization. Advancing cancer diagnosis and ...
based inSaint-Herblain Cedex, FRANCE
Atlanthera is a drug discovery company focused on bone diseases and bone cancer treatments. The growing medical need and the lack of effective treatments for bone tumors gave rise to Atlanthera in 2011, a drug discovery company focused on bone ...
based inHolytown, UNITED KINGDOM
We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to ...
TCB006 is an allogeneic CAR-T product targeting B7-H4 for the treatment of cancers arising from solid tumors. B7-H4 antigen is overexpressed in breast cancers, especially triple negative breast cancer, and ovarian cancers, both diseases with ...
based inNotting Hill, AUSTRALIA
Cartherics is developing its novel “off-the-shelf” (allogeneic) immune therapy products for the treatment of cancer based on immune killer cells. The company is developing large-scale manufacture of these CAR-iNK cells for application in human ...
based inTucson, ARIZONA (USA)
Novel therapeutics are lacking for Brain Cancer. Only four of the 217 FDA-approved oncology medicines are indicated for life-threatening brain cancers. The most recent approval was in 2009 and did not extend life expectancy. Patients deserve better ...
Only 4 of the 217 FDA-approved oncology medicines are indicated for life-threatening brain cancers. The most recent approval was in 2009, but this medicine did not extend life expectancy. Patients deserve better therapies that extend life and ...
based inMilano, ITALY
BetaGlue Technologies can deliver a localized amount of energy via a simple, intra-operative, internal radiotherapy platform engineered to achieve maximum efficacy and much improved safety for the patients. A new anti-tumoral compound based on 90Y ...
Surgery is the standard of care for resectable solid tumors. Loco-regional approaches, in combination with chemotherapy and/or radiotherapy, are standard therapy in the following ...